Neurocrine Biosciences, Inc.

NASDAQ:NBIX

123.02 (USD) • At close May 30, 2025
Bedrijfsnaam Neurocrine Biosciences, Inc.
Symbool NBIX
Munteenheid USD
Prijs 123.02
Beurswaarde 12,174,772,716
Dividendpercentage 0%
52-weken bereik 84.23 - 157.98
Industrie Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Dr. Kevin C. Gorman Ph.D.
Website https://www.neurocrine.com

An error occurred while fetching data.

Over Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive

Vergelijkbare Aandelen

DENTSPLY SIRONA Inc. logo

DENTSPLY SIRONA Inc.

XRAY

15.98 USD

Repligen Corporation logo

Repligen Corporation

RGEN

118.07 USD

Exact Sciences Corporation logo

Exact Sciences Corporation

EXAS

56.28 USD

Bruker Corporation logo

Bruker Corporation

BRKR

36.7 USD

Maravai LifeSciences Holdings, Inc. logo

Maravai LifeSciences Holdings, Inc.

MRVI

2.25 USD

NovoCure Limited logo

NovoCure Limited

NVCR

19.11 USD

Masimo Corporation logo

Masimo Corporation

MASI

162.5 USD

Jazz Pharmaceuticals plc logo

Jazz Pharmaceuticals plc

JAZZ

108.07 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)